A prospective clinical study concerning the quantitative evaluation of skin disorders caused by molecular-targeted agents

A prospective clinical study concerning the quantitative evaluation of skin disorders caused by molecular-targeted agents - An observational study toward the prediction of skin disorders caused by anti-EGFR antibody drugs and their clinical application

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041267

Enrollment

Registered

2020-07-31

Start date

2018-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all of the following conditions may participate in this study: 1) A male and female patient older than 20 years 2) A patient diagnosed with cancer 3) A patient who will receive anti-EGFR antibody drugs for the first time as cancer treatment 4) A patient who can provide written consent to participate in this study

Exclusion criteria

Exclusion criteria: Patients who meet any of the following conditions will be excluded from the study: 1) A patient with a skin disease such as psoriasis or atopic dermatitis 2) A patient deemed unfit to participate by the doctor

Design outcomes

Primary

Measure	Time frame
The relationship between skin conditions and skin disorders caused by anti-EGFR antibody drugs	—

Secondary

Measure	Time frame
Analysis of the changes in skin conditions and risk factors for the manifestation of skin disorders after anti-EGFR antibody drug use	—

Countries

Japan

Contacts

Public ContactHiroaki Takahashi

School of Pharmacy, Iwate Medical University Department of Clinical Pharmacy, Division of Clinical Pharmaceutics and Pharmacy Practice

hiroaki.takahashi@j.iwate-med.ac.jp+81-19-651-5111

Outcome results